Whitehawk Therapeutics (NASDAQ:WHWK) Downgraded by Wall Street Zen to Strong Sell

Key Points

• Whitehawk Therapeutics has been downgraded from a "hold" rating to a "strong sell" rating by Wall Street Zen, indicating a negative outlook from analysts.
• The company's latest earnings report revealed a loss of ($0.76) per share, significantly missing analysts' expectations, which projected a profit of $0.49.
• Currently, the stock is trading at $1.75, with a market cap of $82.44 million and a price-to-earnings ratio of -29.17.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "strong sell" rating in a research note issued on Saturday.

Whitehawk Therapeutics Stock Performance

Shares of WHWK stock traded up $0.04 on Friday, reaching $1.73. The company's stock had a trading volume of 81,080 shares, compared to its average volume of 151,346. Whitehawk Therapeutics has a 12-month low of $1.37 and a 12-month high of $3.81. The company has a market capitalization of $81.53 million, a PE ratio of -28.83 and a beta of 0.55.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.49 by ($1.25). Whitehawk Therapeutics had a negative return on equity of 75.99% and a net margin of 99.42%.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.